Diana F. Clarke, PharmD
Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
Infectious Diseases

PharmD, State University of New York at Buffalo
BS, University of Rhode Island College of Pharmacy

Diana Clarke, Pharm.D., is an Assistant Professor of Pediatrics in Infectious Diseases at the Chobanian and Avedisian School of Medicine and Pediatric HIV Pharmacotherapy Specialist at Boston Medical Center. She works in the Pediatric ID clinic and the High-Risk OB clinic where she is actively involved in the management of children and pregnant women living with HIV. Her commitment to pediatrics is demonstrated through her memberships to the WHO Pediatric Antiretroviral Working Group and as a Consultant, Human Resources and Services Administration, HIV/AIDS Bureau (HRSA) for the DHHS Pediatric and Perinatal HIV Guidelines Committees. Her research interests include neonatal pharmacokinetics of antiretroviral agents and pharmacokinetics of anti-infectives in pregnant women. She is currently Chair of several IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials Network, NIH) protocols and a member of the IMPAACT Scientific Treatment Committee.

IMPAACT 2023: A Phase I Study of the Safety and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1
07/01/2022 - 06/30/2025 (PI)
Johns Hopkins University ViiV Healthcare

IMPAACT Protocol Leadership: 2032 Protocol Vice Chair Remdesevir
07/01/2023 - 11/30/2023 (PI)
Johns Hopkins University National Institute o

IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States
12/01/2021 - 11/30/2023 (PI)
Johns Hopkins University Gilead Sciences

LOC-IMPAACT Leadership Group: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the US
06/01/2020 - 11/30/2022 (PI)
Johns Hopkins University National Institute o

LOC-IMPAACT Leadership Group - IMPAACT 2023/P1097 Protocol Chair
12/01/2018 - 06/30/2022 (PI)
Johns Hopkins University National Institute o

LOC-IMPAACT Leadership Group - Merck 1097P
01/01/2020 - 12/31/2020 (PI)
Johns Hopkins University Merck

P1097A – TO# LDR 04 MOD 03 – Raltegravir Pharmacokinetics and Safety in Neon…..
01/01/2014 - 11/30/2020 (PI)
Johns Hopkins University Merck

P1097A - TO# LDR 04 MOD 02 - Raltegravir Pharmacokinetics and Safety in Neonates
01/01/2014 - 10/01/2020 (PI)
Johns Hopkins University NIH-NIAID

LOC-IMPAACT Leadership Group - JHU P1097 and P1110
01/01/2014 - 11/30/2015 (PI)
Johns Hopkins University NIH-NIAID
5 UM1 AI068632-09

IMPAACT Leadership Award: Chair, Protocol P1097
06/01/2012 - 12/31/2013 (PI)
Johns Hopkins University NIH-NIAID

Showing 10 of 14 results. Show All Results


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Liu XI, Dallmann A, Brooks K, Best BM, Clarke DF, Mirochnick M, van den Anker JN, Capparelli EV, Momper JD. Physiologically-based pharmacokinetic modeling of remdesivir and its metabolites in pregnant women with COVID-19. CPT Pharmacometrics Syst Pharmacol. 2023 Feb; 12(2):148-153.View Related Profiles. PMID: 36479969; PMCID: PMC9877749; DOI: 10.1002/psp4.12900;
  2. Piscitelli J, Nikanjam M, Best BM, Acosta E, Mirochnick M, Clarke DF, Capparelli EV, Momper JD. Optimizing Dolutegravir Initiation in Neonates Using Population Pharmacokinetic Modeling and Simulation. J Acquir Immune Defic Syndr. 2022 01 01; 89(1):108-114.View Related Profiles. PMID: 34629412; PMCID: PMC8665018; DOI: 10.1097/QAI.0000000000002830;
  3. Epstein RL, Penwill N, Clarke DF, Hamilton S, Horbowicz K, Dorfman D, Moses JM, Cooper ER. "Meds-in-Hand" Intervention to Reduce Critical Process Delays in Pediatric Human Immunodeficiency Virus Post-Exposure Prophylaxis. J Pediatric Infect Dis Soc. 2021 Mar 26; 10(2):196-200.View Related Profiles. PMID: 32347312; PMCID: PMC7996639; DOI: 10.1093/jpids/piaa033;
  4. Clarke DF, Lommerse J, Acosta EP, Cababasay MP, Wang J, Spector SA, Chain A, Smith E, Teppler H, Hazra R, Calabrese K, Graham B, Popson S, Bryson Y, Mirochnick M. Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097. J Acquir Immune Defic Syndr. 2020 12 15; 85(5):626-634.View Related Profiles. PMID: 32925360; PMCID: PMC8043209; DOI: 10.1097/QAI.0000000000002492;
  5. Clarke DF, Acosta EP, Cababasay M, Wang J, Chain A, Teppler H, Popson S, Graham B, Smith B, Hazra R, Calabrese K, Bryson Y, Spector SA, Lommerse J, Mirochnick M. Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110). J Acquir Immune Defic Syndr. 2020 05 01; 84(1):70-77.View Related Profiles. PMID: 31913995; PMCID: PMC7144886; DOI: 10.1097/QAI.0000000000002294;
  6. Clarke DF, Mirochnick M, Acosta EP, Capparelli E, Chain A, Teppler H, Smith B, Lommerse J. Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110. J Acquir Immune Defic Syndr. 2019 12 01; 82(4):392-398.View Related Profiles. PMID: 31658182; PMCID: PMC6820708; DOI: 10.1097/QAI.0000000000002149;
  7. Schreiner CN, Ahlfors CE, Wong RJ, Stevenson DK, Clarke DF, Mirochnick M. In Vitro Study on the Effect of Maraviroc or Dolutegravir on Bilirubin to Albumin Binding. Pediatr Infect Dis J. 2018 09; 37(9):908-909.View Related Profiles. PMID: 29561509
  8. Clarke DF, Penazzato M, Capparelli E, Cressey TR, Siberry G, Sugandhi N, Mirochnick M. Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. Expert Rev Clin Pharmacol. 2018 Jan; 11(1):83-93.View Related Profiles. PMID: 29039686
  9. Clarke DF, Yildirim I, Cooper ER. Rapid Initiation of Antiretrovirals in Two Newly Diagnosed HIV-infected Infants. Pediatr Infect Dis J. 2017 Jan; 36(1):61-62.View Related Profiles. PMID: 27749654
  10. Clarke DF, Acosta EP, Rizk ML, Bryson YJ, Spector SA, Mofenson LM, Handelsman E, Teppler H, Welebob C, Persaud D, Cababasay MP, Wang J, Mirochnick M. Raltegravir pharmacokinetics in neonates following maternal dosing. J Acquir Immune Defic Syndr. 2014 Nov 1; 67(3):310-5.View Related Profiles. PMID: 25162819; PMCID: PMC4197108; DOI: 10.1097/QAI.0000000000000316;
Showing 10 of 16 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 16 publications over 12 distinct years, with a maximum of 2 publications in 2000 and 2017 and 2020 and 2022


Contact for Mentoring:

72 E. Concord St Instructional (L)
Boston MA 02118
Google Map

Clarke's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department